Home health provider Amedisys said Thursday it will begin offering in-home molecular testing to patients that will help quickly identify urine, respiratory and wound infection pathogens.
The Baton Rouge, Louisiana-based company is providing advanced molecular testing through a partnership with Patients Choice Laboratories.The process delivers rapid and precise results that can result in quicker treatment interventions and prevent hospitalizations, Barbara Andazola, Amedisys vice president of Clinical Practice, Strategy and Programs, said in a press release.
Related: UnitedHealth Group's Optum to acquire Amedisys
The company said it has implemented comprehensive protocols and staff training to ensure the process is seamlessly integrated into patient care.
Amedisys is one of the nation’s largest providers of home health, hospice and hospital-at-home services in the United States. The company offers home-based care to nearly 470,000 patients in 37 states, with approximately 19,000 employees.
Amedisys agreed to be acquired last June by UnitedHealth Group’s Optum for $3.3 billion. The deal is still undergoing regulatory review.
